Portopulmonary hypertension

• Main Author: Saleemi Sarfraz
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2010-01-01
• Series: Annals of Thoracic Medicine
• Subjects: Liver transplant; portopulmonary hypertension; pulmonary arterial hypertension; portal hypertension; vasodilator therapy
• Online Access: http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2010;volume=5;issue=1;spage=5;epage=9;aulast=Saleemi
• ISSN: 1817-1737; 1998-3557

Portopulmoanry hypertension (POPH) is a form of pulmonary arterial hypertension (PAH) associated with portal hypertension with or without underlying chronic liver disease. POPH is increasingly recognized and recent evidence suggests that it is one of the leading causes of PAH. The pathophysiology of POPH is poorly understood although the pathological changes in pulmonary vasculature in advanced POPH are similar to those seen in idiopathic pulmonary hypertension. The prognosis in patients with liver disease who also suffer from significant POPH is considered to be poor. Higher degree of pulmonary artery pressure (PAP) may preclude a patient from liver transplant as mortality in these patients is high. The treatment with vasodilator therapy has shown to improve both hemodynamics and clinical outcome in POPH in retrospective studies and in some case series. The aim of medical management is to bring PAP < 35 mmHg that may make a patient with POPH and advanced liver disease eligible for liver transplant, which otherwise would have been denied because of high PAP.